G3BP1与乳腺癌内分泌治疗耐药的相关性研究

The correlation between G3BP1 and endocrine therapy resistance in breast cancer

目的探讨G3BP1与乳腺癌内分泌治疗耐药的相关性。方法全面检索高通量基因表达数据库(GEO),分析G3BP1 mRNA在乳腺癌内分泌治疗耐药细胞株中的表达水平。收集Luminal型患者乳腺肿瘤蜡块标本41例,分为原发耐药组、继发耐药组、敏感组3组并进行免疫组化染色,分析G3BP1蛋白在各组肿瘤标本中的表达情况。结果GEO数据库结果显示,与内分泌治疗敏感株比较,耐药株中的G3BP1 mRNA表达水平升高(P<0.05)。G3BP1蛋白在原发耐药组中的高表达率高于继发耐药组(84.62%vs 30.00%,P<0.01)和敏感组(84.62%vs 28.60%,P<0.01)。结论G3BP1与乳腺癌内分泌治疗耐药密切相关,G3BP1高表达容易引起原发内分泌耐药。

Objective To investigate the correlation between G3 BP1 and endocrine therapy resistance.Methods Gene Expression Omnibus( GEO) database was retrieved to analyze the expression of G3 BP1 mR NA in breast cancer resistant cell lines. 41 specimens of Luminal-like breast tumor were collected and divided into three groups:primary endocrine resistance group,secondary endocrine resistance group and sensitive group. The expression of G3 BP1 protein in each group was analyzed by immunohistochemical staining. Results GEO database showed the expression of G3 BP1 mR NA in endocrine therapy resistant cell lines was higher than that in sensitive cell lines( P< 0. 05). The expression of G3 BP1 protein in primary endocrine resistance group was higher than that in secondary endocrine resistance group( 84. 62% vs 30. 00%,P < 0. 01) and sensitive group( 84. 62% vs 28. 60%,P <0. 01). Conclusion G3 BP1 is closely related to endocrine therapy resistance in breast cancer. The high expression of G3 BP1 may lead to primary endocrine resistance.